Twenty-six patients with advanced Hodgkin's disease received a related HLA haploidentical unmanipulated BMT, following a nonmyeloablative conditioning with low-dose TBI, proposed by the Baltimore group; GvHD prophylaxis consisted of high-dose posttransplantation CY (PT-CY), mycophenolate and a calcineurin inhibitor. All patients had received a previous autograft, and 65% had active disease at the time of BMT. Sustained engraftment of donor cells occurred in 25 patients (96%), with a median time to neutrophil recovery (40.5 Â 10 9 /L) and platelet recovery (420 Â 10 9 /L) of þ 18 and þ 23 days from BMT. The incidence of grade II-IV acute GVHD and of chronic GVHD was 24% and 8%, respectively. With a median follow-up of 24 months (range 18-44) 21 patients are alive, 20 disease free. The cumulative incidence of TRM and relapse was 4% and 31%, respectively. The actuarial 3-year survival is 77%, the actuarial 3-year PFS is 63%. In conclusion, we confirm that high-dose PT-CY is effective as prophylaxis of GVHD after HLA haploidentical BMT, can prevent rejection and does not appear to eliminate the allogeneic graft versus lymphoma effect.
INTRODUCTION
Hodgkin's lymphoma (HL) is the paradigm of curable hematological malignancy using chemotherapy and radiotherapy, even in patients with advanced disease. 1 However, a small proportion of patients do not respond to initial treatment or experience early relapse. 1 In these patients, salvage chemotherapy followed by high-dose chemotherapy (HDC) with autologous stem cells has become the gold standard treatment producing longterm remissions in approximately 40-50% of relapsed patients [2] [3] [4] and in up to 25-30% of those with primary refractory disease. 5, 6 Nevertheless, a substantial number of patients will also relapse after HDC and will require further therapy. In this setting, an allo-SCT folllowing reduced intensity conditioning or nonmyeloablative regimens (NMA) has been shown to be feasible [6] [7] [8] [9] [10] [11] [12] [13] [14] and superior in terms of survival and PFS, when compared with other therapeutic options. 15 The problem with an allo-SCT is that the majority of patients lack an identical sibling and no more than 50% of patients, searching the Registries for unrelated donors or cord blood units, undergo an allo-SCT (World Marrow Donor Association data, 2012 unpublished). Recently, encouraging results have been obtained with HLA haploidentical-related donor, following an NMA regimen, unfractionated BM and post-transplantation CY (PT-CY). 16 High-dose PT-CY given early after BM infusion is supposed to kill alloreactive donor and host T cells, thus reducing the incidence of GVHD and graft rejection. Furthermore, PT-CY does not affect engraftment due to the enzymatic resistance of hemopoietic stem cells to CY, possibly, because most stem cells are not dividing. 17 In a retrospective study, the Baltimore group showed that the outcome of HL patients receiving a haploidentical transplant with PT-CY is comparable, if not superior, to the outcome of patients grafted from HLA identical sibling or unrelated donors. 18 The aim of this retrospective study was to confirm the reproducibility of the procedure in terms of toxicity and efficacy in a cohort of HL patients treated in two institutions.
PATIENTS AND METHODS
This is a retrospective analysis of 26 poor prognosis HL patients who received an HLA haploidentical transplant between April 2009 and March 2011. Clinical characteristics are outlined in Table 1 . Patients received transplantation from a related haploidentical donor, with an NMA conditioning regimen and PT-CY, if an HLA identical or MUD were unavailable, and all had received a previous autograft for refractoriness or progression after conventional salvage chemotherapy.
Conditioning regimen and GVHD prophylaxis
The conditioning regimen consisted of Cy 14.5 mg/kg on days À 6 and À 5, fludarabine 30 mg/m 2 /day from day À 6 to day À 2 and low dose TBI (2 Gy) on day À 1.
15 GVHD prophylaxis consisted of Cy 50 mg/kg given on days þ 3 and þ 4, tacrolimus (1 mg total dose, i.v. as a continuous infusion) or CyA (2 mg/kg/day i.v. as a continuous infusion) and MMF (15 mg/kg 2 per day) until day þ 30. In five patients, CyA was started at day À 1. In all other patients, FK or CyA was started at day þ 5. G-CSF was started at day þ 5 in all patients.
Stem cell source
Unmanipulated BM was the stem cell source in all the patients on day 0. Donors underwent BM harvest under general anesthesia, and the ideal target of mononuclear cells was 4 Â 10 8 /kg.
Donors
Family donors were all genotypically HLA haploidentical and had a minimum of two antigenic A, B, DR differences on the unshared haplotype.
Supportive care
Antimicrobial prophylaxis was started during conditioning regimen and consisted of acyclovir 500 mg/m 2 three times in day, levofloxacine 500 mg per day, cotrimoxazole two tablets per day until day À 2 and then resumed after hematological reconstitution one tablet every other day. Fungal prophylaxis in most patients consisted of fluconazole 400 mg per days until day þ 75; 11 patients received caspofungin (70 mg first day and then 50 mg) until day þ 5, when i.v. itraconazole (200 mg) was administered. Biweekly cytomegalovirus (CMV) monitoring, by PCR or antigenemia, was started at day þ 15 until day þ 100 and weekly until day þ 180. Treatment with gancyclovir or foscarnet was started for positive PCR or antigenemia. Weekly Epstein-Barr virus (EBV) monitoring by PCR was started at day þ 15, and Rituximab (375 mg/m 2 ) was administered if 410 4 copies/ml or 410 3 copies/10 4 cells were detected.
DLI
Patients experiencing relapse were eligible for chemotherapy and DLI: the dose of DLI started at 1 Â 10 3 /kg CD3 þ cells and was increased every 1-2 months by half log, up to 1 Â 10 7 /kg.
Statistical analysis
Survival analysis was performed by plotting survival curves according to the Kaplan-Meier method. The study population was stratified for principal clinical characteristics and groups were compared by means of the log rank test. All statistical analyses were performed using the NCSS7 package (NCSS7, Kaysville, UT, USA).
RESULTS
Patient characteristics are reported in Table 1 . All patients received at least two conventional chemotherapy lines, and all patients received an autologous transplant: 21 relapsed after HDC and autologous PBSC. Five patients refractory to salvage chemotherapy were treated in an auto-allo program consisting of an HDC with melphalan (200 mg/m 2 ) plus autologous PBSC, and after a median time of 53 days (40-91), they received a haploidentical transplantat. At the time of transplant, 17 patients (65%) had detectable disease, and 8 of those were in stable/progressive disease.
Engraftment
The median numbers of mononuclear and CD34 þ marrow cells infused were 4 Â 10 8 /kg and 3.2 Â 10 6 /kg, respectively. The median times to neutrophil recovery (X0.5 Â 10 9 /L) and platelet recovery (X20 Â 10 9 /L) were 18 days (range 13-32) and 23 (16-51), respectively. The cumulative incidences of neutrophil and platelet engraftment were, respectively, 96% and 92% (Figure 1) . One primary graft failure was observed. Chimerism was evaluable in 25 patients: on day þ 30 all patients had 100% donor chimerism on unfractionated marrow cells, as well as on peripheral blood CD3 þ selected cells.
Immune reconstitution Immunological recovery was evaluated in 15 patients: on day þ 40 after BMT, CD3, CD4, CD8 and CD56 cell counts were, respectively: 206, 64, 148 and 64/cmm. On day þ 100, CD3, CD4, CD8 and CD56 cell counts were, respectively: 219, 149, 107, 51/cmm.
Infections
The conditioning regimen was well tolerated with no severe mucositis. The median time to discharge from hospital was 28 days (18-90). The incidence of CMV reactivation was 42%, and one CMV-related gastritis was diagnosed by endoscopy. EBV DNAemia was detected in 23% of patients, but no EBV-related disease was observed. Hemorrhagic cystitis with BK viriuria was observed in 23% of patients. Other less frequent viral infections were H1N1 pneumonia (8%), respiratory syncitial virus rhinitis (4%) and HHV-6 pneumonia (4%). Overall, 65% of patients showed at least one viral infection.
Bacterial infections were as follows: Gram-negative sepsis (8%), 1 patient had Escherichia Coli cystitis (4%), and Clostridium colitis (4%). Pneumonia of undetermined etiology was observed in two patients (8%).
The incidence of invasive fungal infection was 8%: one patient had aspergillus pneumonia, and one patient had colitis due to candida non-albicans. GVHD Twenty-five patients were evaluable for acute GVHD. The 100-day cumulative incidences of grade I and grade II-IV acute GVHD were 4% and 24%, respectively (Figure 2) . The median time to acute GVHD was 40 days (range 25-73). Twenty-five patients were evaluable for chronic GVHD. The cumulative 3-year incidence of moderate chronic GVHD was 9% (2/23) (Figure 2 ).
Non-relapse mortality (NRM), relapse and survival After a median follow-up for surviving patients of 24 months (range 18-44), the cumulative incidence of NRM was 4% (1/26) ( Figure 2 ). The cause of death was H1N1 diffuse interstitial pneumonia, diagnosed at day þ 21. Relapse was diagnosed in 8 patients, producing a cumulative incidence of relapse at 18 months of 31% (Figure 2) , with a median time to relapse of 5 months (range 1-18): 2 patients never achieved a remission and progressed, whereas 6 additional patients relapsed later.
The actuarial 4-year survival and disease-free survival is 77% and 63%, respectively (Figure 3 ). Disease-free survival was statistically different when patients were stratified for disease phase: 1-year PFS was 100, 67, 37% for patients in CR (n ¼ 9), PR (n ¼ 9) or resistant disease (n ¼ 8), respectively (P ¼ 0.02). Actuarial survival was not statistically different in the three groups (P ¼ 0.1). DLI Six patients received 20 DLI for relapse of their disease, at a median interval of 17 months from transplant (range 5-20 months) following chemotherapy: 3 patients received 3 courses of gemcitabine followed by DLI, while 3 patients received 3 courses of bendamustine þ rituximab followed by DLI. At the moment of first DLI, the chimerism was 100% donor in all patients. The median number of DLI was 4/patient (range 1-5) and the dose of DLI expressed as CD3 þ cells Â 10 
DISCUSSION
We have confirmed in 26 advanced HD patients the results published by the Baltimore/Seattle group, using haplo-mismatched marrow grafts and PT-CY. In our series, the procedure was feasible, with a low rate of GvHD and NRM, and was associated with a durable remission in a high proportion of patients.
Feasibility is relevant due to the poor clinical conditions of HD patients after multiple courses of chemotherapy and, most often, a failed BEAM/autograft: we used the Baltimore NMA, with a combination of fludarabine, CY and a low-dose TBI in all patients. We did not see major complications and NRM was very low (4%), with one patient dying of H1N1 pneumonia. This is in keeping with results reported by the Baltimore group: in their series of high-risk HD receiving haploidentical marrow with PT-CY, 15 NRM was 9%, again very low. This figure should be compared with NRM from other series of patients both grafted from HLA identical siblings or unrelated donors: 18, 19, 20 the average NRM is reported to be 50% for myeloablative regimens and 21% for reduced intensity conditioning. 21 In the San Martino Unit, we could identify 21 HD patients receiving an allograft from an HLA identical sibling and 16 from an alternative donor: their NRM was, respectively, 33% and 37%, with no significant difference according to the intensity of the conditioning regimen. The actuarial 3-year survival of alternative donor transplants was 30%, compared with 77% in this report. Relapses were comparable. Results of the Baltimore group, 15 confirmed by the present series, suggest a significantly lower NRM when using PT-CY, and, with comparable relapse rates, this translates to a superior survival.
Immune reconstitution was relatively fast in our series: the median CD4 þ cell count on day þ 40 and day þ 100 from BMT was, respectively, 64 and 149/cmm. Comparable values were found in recipients from HLA identical siblings. 22 As a consequence, we saw very few serious infections: no patient died of CMV disease or invasive fungal infection or sepsis. There was no post-transplant EBV-associated post-transplant lymphoproliferative disorder. One patient died of H1N1 pneumonia.
Relapse was the major cause of treatment failure in our series, with 31% of patients relapsing after the transplant at a median interval of 5 months from BMT. This result is comparable with the 33-35% relapse rate reported, following reduced intensity conditioning BMT from mismatched unrelated donor or cord blood. 18, 19, 20 In our series, most patients had already failed an autologous transplant, most had progressive disease at BMT or short lived responses after chemotherapy. There were only two patients, who were truly refractory to chemotherapy and radiotherapy from diagnosis: they also had progressive disease after haplo-BMT and died 2 months after transplant. All other patients (24/26), who can thus be considered chemosensitive, though with short-lived remission, were studied with a PET (positron emission tomography) scan 3 months post BMT and all 24 were found to be PET negative. With longer follow-up, six additional patients relapsed. Three additional patients had a positive PET scan, but lymphnode histology disproved relapse of the original disease and showed a polyclonal B-cell reconstitution: long-term follow-up (8-14 months) of these patients confirms that they are still in remission. Therefore histology is recommended to prove relapse of the original disease, in keeping with other reports. 23 Patients with overt or histological-proven relapse were treated with chemotherapy and DLI: 50% of treated patients are disease free with a median follow-up of 18 months from DLI. The clinical response, observed after chemotherapy and donor lymphocyte infusions, together with a high number of patients who remain in CR with a 63% disease-free survival at 4 years, would suggest the existence of a graft-versus-Hodgkin's lymphoma effect, operating in the setting of haplo-transplants and PT-CY. 24, 25 An additional comment should be made on our experience with DLI: the lack of GvHD following several DLI, as well as the very low overall rate of GvHD, would point to allogeneic tolerance, actively maintained by regulatory T cells, without counteracting GvL.
In conclusion, we have reproduced the Baltimore data in highrisk HD patients receiving an unmanipulated haplo-transplant and PT-CY after failing several lines of therapy. Relapse, post transplant, remains a problem, especially in the truly chemorefractory patients, and may be possibly addressed by scheduling a haplo-transplant, earlier in the course of the disease. The use of the newly available anti-CD30 moAb, which we have not explored in this series, may be an additional important tool to bring patients to transplant with a smaller burden of disease.
